Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jerome A. Hubsher"'
Autor:
Dodda Leelavathi, Soong T. Chiang, Kenneth C. Lasseter, Frank W. Janssen, Eugene R. Fluck, Jerome A. Hubsher
Publikováno v:
The Journal of Clinical Pharmacology. 24:515-522
Twelve normal subjects each received single 300-, 600-, and 1200-mg oral doses of oxaprozin according to a three-period crossover design. Total drug plasma concentrations did not increase in proportion to the dose administered. Total clearance (CIo)
Publikováno v:
The Journal of Clinical Pharmacology. 21:157-161
Oxaprozin, a new long-acting, antiinflammatory agent, and aspirin were compared utilizing gastroscopic evaluation and photography of the gastric mucosa in a double-blind, crossover study in normal volunteers. Submucosal hemorrhages or mucosal bleedin
Publikováno v:
The Journal of Clinical Pharmacology. 14:118-126
Autor:
S. Benham Kahn, Jerome A. Hubsher
Publikováno v:
The Journal of Clinical Pharmacology. 23:139-146
Oxaprozin, a new nonsteroidal antiinflammatory agent, was studied alone and in combination with aspirin for its effects on hemostasis and protein binding in 10 healthy adults. When both oxaprozin and aspirin were given separately for seven days and i
Autor:
Jerome A. Hubsher
Publikováno v:
American Heart Journal. 61:467-475
The electrocardiograms of normal fullterm infants and of children 1–7,17 have been thoroughly studied and reported upon, but few studies have been done on the premature infant. It is the purpose of this paper to report the results of a study of the
Publikováno v:
The Journal of international medical research. 7(1)
Preliminary clinical studies showed that oxaprozin (4,5 Diphenyl-2-oxazolepropionic acid) has anti-inflammatory and analgesic properties with a plasma half-life of about 40 hours. Consequently, a multicentre, double-blind parallel trial was conducted
Publikováno v:
Journal of clinical pharmacology. 24(8-9)
Twelve healthy volunteers received single 1200-mg oral doses of oxaprozin while fasting and immediately after a standard breakfast in a two-period crossover design with three weeks between administrations. Oxaprozin plasma concentrations were monitor